Home / Leaderboard / Casdin Capital, LLC
Casdin Capital, LLC
Eli Casdin · Hedge Fund · Long/Short Equity
Casdin Capital, LLC is a New York-based investment firm specializing in the life sciences and healthcare sectors. Founded in 2011 by Eli Casdin, the firm manages a concentrated portfolio of high-conviction positions across both public and private markets. Its investment focus spans biotechnology, medical devices, diagnostics, and synthetic biology, aiming to capitalize on disruptive technologies that transform healthcare. The firm leverages deep scientific diligence and a thematic approach to identify underappreciated growth opportunities at the intersection of science and financial markets.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +90.1% |
| YTD return | +37.1% |
| Sharpe ratio | 4.46 |
| Win rate | 65% |
| AUM | $1.9B |
| Inception | Oct 1, 2025 |
| Updated | Aug 20, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.9B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.casdincapital.com/ |
Current Holdings
Updated on Aug 20, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| RVMD | Revolution Medicines Inc | 26.8% | +242.7% |
| RLAY | Relay Therapeutics Inc | 14.4% | +143.6% |
| WGS | GeneDx Holdings Corp. | 14.3% | -7.8% |
| BLFS | BioLife Solutions Inc | 8.5% | +43.2% |
| TXG | 10X Genomics Inc | 5.7% | +190.3% |
| ILMN | Illumina Inc | 5.3% | +89.2% |
| LAB | Standard Biotools Inc | 3.7% | -43.3% |
| GPCR | Structure Therapeutics Inc. American Depositary Shares | 3.1% | +60.0% |
| GH | Guardant Health Inc | 2.7% | +82.3% |
| NGNE | Neurogene Inc | 2.6% | +82.4% |
| DNLI | Denali Therapeutics Inc | 2.3% | +32.1% |
| BEAM | Beam Therapeutics Inc | 1.9% | +8.1% |
| PSNL | Personalis Inc | 1.2% | +46.5% |
| HIMS | Hims Hers Health Inc | 1.1% | +28.5% |
| AGMB | AgomAb Therapeutics NV American Depositary Shares | 1.1% | +16.9% |
| SEPN | Septerna, Inc. Common Stock | 1.1% | +30.1% |
| MAZE | Maze Therapeutics, Inc. Common Stock | 1.1% | +0.1% |
| TSHA | Taysha Gene Therapies Inc | 1.1% | +9.5% |
| SRRK | Scholar Rock Holding Corp | 0.9% | +18.7% |
| ALNY | Alnylam Pharmaceuticals Inc | 0.8% | +5.3% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 10, 2026 | SELL | NGNE | 2.6% → 2.6% |
| Aug 10, 2026 | BUY | RLAY | 14.7% → 14.4% |
| Aug 10, 2026 | SELL | GRAL | 0.9% → 0.0% |
| Aug 10, 2026 | BUY | WGS | 13.6% → 14.3% |
| Aug 10, 2026 | BUY | BLFS | 8.2% → 8.5% |
Investment Style Analysis
Casdin Capital, LLC is widely recognized for employing a Long/Short Equity strategy. As of Aug 20, 2026, the firm oversees approximately $1.9B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Diagnostics & Research sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 10, Casdin Capital, LLC made a significant move by reducing the position in NGNE. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
The firm employs a primary research-intensive approach that is thematically driven and fundamentally based, focusing on large markets undergoing paradigm shifts due to new technology. Their philosophy is centered on 'investment conviction,' which they build by becoming subject-matter experts through deep scientific diligence and adaptive learning. They maintain a concentrated, high-conviction portfolio, seeking superior long-term risk-adjusted returns by investing in underappreciated companies with innovative business models in the life sciences and healthcare industry.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Casdin Capital, LLC.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +24.1%
- Glenview Capital Management, LLC — Larry Robbins · 3M +14.0%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +3.7%
- Redmile Group, LLC — Jeremy Green · 3M +19.6%
Frequently asked questions
How is the simulated portfolio for Casdin Capital, LLC constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Casdin Capital, LLC's largest holding?
As of the latest filing, Casdin Capital, LLC's top position is Revolution Medicines Inc (RVMD), representing 26.8% of the portfolio. This reflects a high-conviction bet by the institution.
What is Casdin Capital, LLC's historical performance and risk profile?
Our simulation indicates a total return of +90.1% with a win rate of 65%. Notably, the portfolio maintains a Sharpe Ratio of 4.46, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Casdin Capital, LLC primarily invest in?
Casdin Capital, LLC has a strong preference for the Biotechnology sector, which makes up 57.4% of their disclosed assets. The portfolio also has exposure to Diagnostics & Research, indicating a specific thematic focus.
Is Casdin Capital, LLC's portfolio concentrated or diversified?
Casdin Capital, LLC runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 55.5% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Casdin Capital, LLC performed in 2026?
Our AI-simulated model portfolio for Casdin Capital, LLC tracks a Year-to-Date (YTD) return of +37.1%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Eli Casdin manage Casdin Capital, LLC directly?
Yes, Eli Casdin serves as the key portfolio manager for Casdin Capital, LLC, overseeing the investment strategy and final capital allocation decisions.